Keryx A Buy @ The Motley Fool (KERX)

Keryx A Buy @ The Motley Fool (KERX)

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of ZerenexTM for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA.

At The Motley Fool, contributor Jordo Bivona writes that "There is no shame in wanting to find cheap investments that pay off in the long run. The trouble is it can be tough to tell what is worth your money and what is cheap simply because it is worthless." In some cases, like Keryx, "the prices are low, but the stocks are worth a great deal. For these stocks, now is the time to buy and hang on until something major happens and the prices soar."

About Keryx, he writes,

"Keryx (NASDAQ: KERX) is currently selling for around $1.50 and has been floundering, primarily because its flagship drug perifosine failed its latest round of clinical trials. The drug was intended to offer a new treatment option for those suffering from colorectal cancer. When it did not live up to expectations, Keryx plummeted more than 60% and continues to fall.

...The company still has approximately $30 million in cash to fund operations, and a quarterly burn rate of around $4 million to $6 million, depending on research demands. For the company to succeed with Zerenex, it needs successful trials in its fourth quarter and a new drug application from the FDA. Recently, the stock saw a 22% gain on news of a successful clinical trial for Zerenex that was completed in Japan. Thus, this stock may be down, but it is definitely not out."

Read more at beta.fool.com.